TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: baroreflex sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Erythrocyte fluidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Erythrocyte aggregation tendency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to peak plasma concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dry eye sensation
Endpoint domain: Adverse events/effects
Primary endpoint: Body discomfort during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: student performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: postintervention absolute BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of total infections
Endpoint domain: Adverse events/effects
Primary endpoint: First analgesic demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Number of circulating lymphocytes responding to Ni
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sustained clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drug-free remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour quit attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day quit attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month continuous abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proprioceptive deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in BDI scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in life satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CO2 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean hand pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hsIL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of abdominal compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of abdominal compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year cumulative survival rates
Endpoint domain: Mortality/survival
Primary endpoint: excess mortality rate for AA children compared with white children
Endpoint domain: Mortality/survival
Primary endpoint: excess mortality rate for SS children compared with white children
Endpoint domain: Mortality/survival
Primary endpoint: improvements in planning/organizing skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tinnitus symptoms (THI scores)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hospital admissions due to acute exacerbation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: mean increases in milk volume per participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduction of pure-tone tinnitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in Beck Depression Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvements in tinnitus questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in mean HAM-D scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of substantial EPS
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of at least moderate EPS
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Hyperactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of mastectomy, chemotherapy, immediate breast reconstruction or post-mastectomy radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: RPQ symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to recall specific events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Major or fatal bleeding episodes
Endpoint domain: Adverse events/effects
Primary endpoint: mean maximum serum estradiol concentrations (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean maximum serum estrone concentrations (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: skin irritation
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality or first hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: frequency of COPD exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quality of Well‐Being Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of screen-positive patients not given advice
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: sustained smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic imbalance between GABA and glutamate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: daylong glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VZV-specific CMI levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SF-36 scores for physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Depth of penetration of embolic particles into leiomyomata
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower limb spasticity (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Passive range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Continence rate at 1 year postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in FACIT-F total quality-of-life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in ESAS physical distress scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in plasma sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in chloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: patient and graft survival
Endpoint domain: Mortality/survival
Primary endpoint: infections
Endpoint domain: Adverse events/effects
Primary endpoint: CD4 cell count < 400 x 10 cells/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum methaemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: post-operative VAS score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: number of transfused red blood cell units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete ablation rate after one month
Endpoint domain: Adverse events/effects
Primary endpoint: Local tumor progression rates
Endpoint domain: Mortality/survival
Primary endpoint: Mean time to progression (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum bite force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of relapse after drug discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: median growth of the left lateral segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of 18F-FDG PET reporting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-adjusted life year (QALY) gained
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: (18)F‐FLT uptake correlation with proliferation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Basal jejunal fluid absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time to ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: exercise tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient outcomes after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL cholesterol improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical duration of effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Train-of-four (TOF) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of cisatracurium used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: NYHA functional class
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: plasma C-peptide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VLDL-triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS scores during balloon dilatation, bone cement injection and soon after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to undergo reoperation
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Response to CRT (Cardiac Resynchronization Therapy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bruxism index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of aortic dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of aortic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Survival curve differences
Endpoint domain: Mortality/survival
Primary endpoint: patient safety outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (AQLQ scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health-care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Oxygen Desaturation Index (ODI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Epworth Sleepiness Scale (ESS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional Outcomes of Sleep Questionnaire (FOSQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: FVIIa plasma activity half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-progression survival
Endpoint domain: Mortality/survival
Primary endpoint: Pulp canal obliteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge grade difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of counselling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in sugar purchased
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in calories purchased
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in saturated fat purchased
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: invasive-disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Pplat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cstat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Empowerment and engagement at work
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rates of high depersonalization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of residents referred to a medical practitioner for further assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in manic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in global functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean LV early diastolic strain rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to local recurrences, lymphatic or distant metastases
Endpoint domain: Mortality/survival
Primary endpoint: Psychosomatic self-regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient tolerance for the introduction of the echoendoscope
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: overall morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discharge from the hospital
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute bioavailability of bromfenac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving hydroxyurea by hospital day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients inappropriately receiving hydroxyurea
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with a UUI response at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median percentage decrease in UUI episodes/24 h after tolterodine treatment at week 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque severity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epidermal proliferation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: K10 expression improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma triacylglycerol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL-cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GLP-1 and GIP responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat composition in the multifidus muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Suicidal thoughts reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anhedonia as measured by SHAPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alertness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resolution of side effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete/substantial control of sleep disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long jump performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: triple hop right performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 m sprint performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCORAD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cannula malposition rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of death from any cause at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Contrast-Induced Nephropathy (CIN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Seroma formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical pain thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative cultures using liquid medium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to stable culture conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WST-Q performance scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial blood beta‐human chorionic gonadotropin (β‐hCG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: D3‐5/D0 ratio of blood β‐hCG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mood ratings (MADRS and YMRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in IEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuations due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: sense of control improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sense of burden reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: myocardial infarct size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myocardial salvage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of subcutaneous hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Overall internalising symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Separation anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: microvascular reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: markers of vascular repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: ZCQ Symptom Severity and Physical Function scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Axial pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back function assessed with the Oswestry Disability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D(4)/D(0) glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: D/P creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: vascular endothelial growth factor (VEGF) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge retention after 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Nocturnal systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nocturnal diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nocturnal mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of ischaemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in mean diffusivity, axial diffusivity and radial diffusivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes